Store
Artificial Intelligence Markets in In Vitro Diagnostics (IVD)
Publication Date: April 6, 2020
Tags: Artificial Intelligence (AI), Clinical Chemistry, Diagnostic Instruments, Hematology, Immunoassay, Infectious Disease Testing Instruments, Lab Software, Molecular Diagnostics, Oncology and Cancer, Point-of-Care (POC) Testing, Software and Informatics
Pages: 70
SKU: 20-037
Description:
The past few years have seen extraordinary advances in artificial intelligence (AI) in clinical medicine. More products have been cleared for clinical use, more new research-use-only applications have come to market, and many more are in development. In recent years, diagnostics companies, in collaboration with AI companies, have begun implementing increasingly sophisticated machine learning techniques to improve the power of data analysis for patient care. The goal is to use developed algorithms to standardize and aid the interpretation of test data by any medical professional, irrespective of expertise. This way, AI technology can assist pathologists, laboratorians, and clinicians in complex decision-making.
Kalorama’s report, Artificial Intelligence Markets in In Vitro Diagnostics (IVD), examines selected AI-based initiatives, collaborations, and tests in key IVD market segments.
Artificial Intelligence Markets in IVD contains the following important data points:
- The Market for AI in Diagnostics, 2019
- Forecasted Market for 2024
- Breakout of Market by Application, 2019 (Glucose, Histology, Microbiology, Hematology, Biomarker Diagnostic Aids)
- Breakout of Market by Components, 2019 (Hardware, Software, Services)
- Significant Partnerships and Initiatives in AI Related to In Vitro Diagnostics
Key Highlights:
Digital pathology products and diabetes management devices were the first to come to market with data interpretation applications. The last few years have seen the use of AI interpretation apps extended to a broader range of products, including microbiology, disease genetics, and cancer precision medicine. This report will review some of the AI-linked tests and test services that have come to market and others that are in development in some of the following market segments:
- Cancer Diagnostics
- Cardiac Disease Testing
- Digital Pathology
- Genetic Testing
- Glucose Monitoring
- Hematology
- Histology
- Information Technology (including Electronic Medical Records)
- Liquid Biopsy
- Microbiology
- Microbiome
- Molecular Diagnostics
- Next-Generation Sequencing
- Point of Care
- Transplant Risk Testing
- Urinalysis
Applications of AI:
Applications of AI are evolving to predict outcomes such as diagnosis, death, or hospital readmission; to improve upon standard risk assessment tools; to elucidate factors that contribute to disease progression; or to advance personalized medicine by predicting a patient’s response to treatment. AI tools are in use and in development to review data and uncover patterns that can be used to improve analyses and uncover inefficiencies. Many enterprises are joining this effort.
Explore the full report to understand the transformative impact of AI on in vitro diagnostics and how these advancements are shaping the future of patient care.
For further details and to purchase directly, please contact us.
Table: Artificial Intelligence Market in Diagnostics, Market by Component, 2019 (in millions $) (%)
| Component | 2019 | %Mkt |
| Hardware | $XX Million | XX% |
| Software | $XX Million | XX% |
| Services | $XX Million | XX% |
| Total | $XX Million | XX% |
Source: Kalorama Information
Table of Contents
1: Executive Summary
The Artificial Intelligence Boom
The FDA Is Getting Ready
- FDA Awards DNAnexus Contract to Power precisionFDA Collaborative Omics Environment in the Cloud
COVID-19 and Artificial Intelligence
- Deep Learning to Discover Origins of COVID-19
- AI-Assisted App Will Direct Individuals Most At Risk for Having COVID-19
- FDA Allows Remote Use of Philips IntelliSite Pathology Solution during COVID Crisis
- JLK Inspection: RT-PCR COVID-19 Testing with AI-Enhanced Imaging Aid
- Persivia: Ruleset to Triage COVID-19 Testing
- Surgisphere Rapid Test Uses AI to Diagnose COVID-19
- Biofourmis’ AI-Powered Remote Monitoring Platform to Fight COVID-19
Methodology
2: Artificial Intelligence in Diagnostics Markets
AI in Clinical Practice
Selected AI-based Initiatives / Collaborations / Tests
-
- Table 2-1: Selected AI-based Initiatives / Collaborations / Tests
- IBM Watson Health
Blood Typing and Screening
Cancer
- Freenome: Computational Biology and Machine Learning for Cancer Detection
- CompCyst: Big Increase in Identification of Benign Cysts
- Grail: Machine Learning on Cancer Mutations
- Lung Cancer Diagnostics ñ LungLife AI
Cardiac Disease
- Ekoís AFib and Heart Murmur Detection Algorithms
- Machine Learning to Assess the Likelihood of Acute Myocardial Infarction
- Bay Echo Labs: FDA-cleared EF Calculation
Genetic Testing
- GRAIL
- Rady Childrenís Institute for Genomic Medicine
- Pathway Genomics
Glucose Monitoring
- Medtronicís Guardian Connect CGM System
- University of Warwick Develops A.I. Technology for Tracking Blood Glucose
Hematology
Histology
- PathAI and Gilead Evaluating Machine Learning Approaches to Liver Histology Assessment
Information Technology
- Electronic Medical Records: Predictive Analytics and AI
Kidney Disease
- KidneyIntelX: Improved Kidney Testing
Liquid Biopsy
Microbiology
Microbiome
- Viome
Molecular Diagnostics
- Seegene: AI-Inspired Molecular Diagnostics
- Predicine and Flagship Biosciences Collaborate
- Molecular Colorectal Diagnosis
Next-Generation Sequencing
- Siemens
- Curetis Group Company Launches AI-powered Molecular Antibiotic Susceptibility Test
- Oxford Nanopore
- BGI Genomics
- Qiagen
Parasitology
- ARUP-Techcyte: Detection of Parasites and Ova
Pathology
- LabCorp and Philips Collaborate
Point of Care
- Siemens Strengthens Technology Position in Immunoassay Point-of-Care Testing
- Reliant Immune Diagnostics: In-Home Rapid Diagnostic Screening Using AI
Transplant Risk Testing
- CareDX and Predigraft
Urinalysis
- Clever Culture: FDA Cleared Automation of Sample Interpretation
What the Future Holds
3: Market Analysis: Artificial Intelligence in Diagnostics
Size and Forecast Estimate
-
- Figure 3-1: AI in Diagnostics Estimated Market and Forecast, 2019-2024 ($M)
Market by Application
-
- Figure 3-2: Artificial Intelligence Market in Diagnostics: Market Estimate by Application (Histology-based AI, Microbiology, Hematology, Glucose Testing, Biomarker Diagnostic Aids) (%)
Component Market Analysis
-
- Table 3-1: Artificial Intelligence Market in Diagnostics: Market by Component, 2019 (Hardware, Software, Services) ($M, %)
Related products
Hematology and Coagulation Markets, 2023
April 5, 2023
Discover the lucrative $10 billion-dollar market for hematology and coagulation in vitro diagnostic (IVD) testing with Kalorama’s comprehensive report, Hematology and Coagulation Markets, 2023. This analysis delves into the dynamic growth factors driving this market, including new technologies, the aging population, and the increasing demand for decentralized testing.
Key Insights Provided:
- Market sizing…
Price range: $3,000.00 through $4,500.00
Cell and Gene Therapy Deals Analysis, 2021-2024
June 3, 2024
Kalorama Information’s Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024 offers a comprehensive look at the dynamic and rapidly evolving cell and gene therapy market. This report highlights the significant deal-making activities that have taken place from Q1 2021 to Q1 2024, providing valuable insights for companies and…
Price range: $6,300.00 through $9,450.00
Cell Therapy and Gene Therapy Disease Markets, 2023-2029
April 30, 2024
Explore the future of medicine with our in-depth report on cell therapy, gene therapy, and RNA therapy markets. Cell therapy and gene therapy represent a frontier in modern medicine, promising revolutionary treatments by treating the underlying genetic causes of disease and by genetically controlling the body’s immune system. Recent years have seen an increase in…
Price range: $5,000.00 through $7,875.00
